Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model.

Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model.
复制标题

DOI:
10.1038/s41541-017-0029-1
复制
发表时间:
2017
期刊:
影响因子:
9.2
通讯作者:
Warimwe GM
Warimwe GM
中科院分区:
医学1区
文献类型:
--
作者:
Munster VJ;Wells D;Lambe T;Wright D;Fischer RJ;Bushmaker T;Saturday G;van Doremalen N;Gilbert SC;de Wit E;Warimwe GM

文献摘要

参考文献

被引文献

相似文献

中东呼吸综合征冠状病毒(MERS-CoV)是一种新型人畜共患病毒,可导致人类严重呼吸道疾病,病死率接近40%,但没有疫苗可用。在这里,我们评估了ChAdOx1的效用,ChAdOx1是一种有前途的复制缺陷型猿猴腺病毒疫苗载体平台,在人类和单峰骆驼中具有既定的安全性,用于MERS CoV疫苗开发。使用转基因致死BALB/c MERS-CoV小鼠模型,我们表明,单剂量鼻内或肌内免疫ChAdOx 1 MERS,编码全长MERS-CoV刺突糖蛋白,是高度免疫原性的,并赋予针对致死性病毒攻击的保护。免疫途径之间的免疫原性和有效性相当。这些数据为进一步评估ChAdOx 1 MERS疫苗在人类和单峰骆驼(感染的动物宿主)中的作用提供了支持。
Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel zoonotic virus that causes severe respiratory disease in humans with a case fatality rate close to 40%, but for which no vaccines are available. Here, we evaluated the utility of ChAdOx1, a promising replication-deficient simian adenovirus vaccine vector platform with an established safety profile in humans and dromedary camels, for MERS-CoV vaccine development. Using a transgenic lethal BALB/c MERS-CoV mouse model we showed that single dose intranasal or intramuscular immunisation with ChAdOx1 MERS, encoding full-length MERS-CoV Spike glycoprotein, is highly immunogenic and confers protection against lethal viral challenge. Immunogenicity and efficacy were comparable between immunisation routes. Together these data provide support for further evaluation of ChAdOx1 MERS vaccine in humans and dromedary camels, the animal reservoir of infection.
DOI: 10.1038/nrmicro.2016.81
发表时间: 2016-08
期刊: Nature reviews. Microbiology
影响因子: --
作者:
de Wit E;van Doremalen N;Falzarano D;Munster VJ
通讯作者: Munster VJ
DOI: 10.1038/emi.2016.130
发表时间: 2017-01-04
影响因子: 13.2
作者:
Ali MA;Shehata MM;Gomaa MR;Kandeil A;El-Shesheny R;Kayed AS;El-Taweel AN;Atea M;Hassan N;Bagato O;Moatasim Y;Mahmoud SH;Kutkat O;Maatouq AM;Osman A;McKenzie PP;Webby RJ;Kayali G
通讯作者: Kayali G
DOI: 10.1016/j.antiviral.2017.03.025
发表时间: 2017-07
期刊: Antiviral research
影响因子: 7.6
作者:
van Doremalen N;Falzarano D;Ying T;de Wit E;Bushmaker T;Feldmann F;Okumura A;Wang Y;Scott DP;Hanley PW;Feldmann H;Dimitrov DS;Munster VJ
通讯作者: Munster VJ
DOI: 10.1128/jvi.02009-15
发表时间: 2016-01-01
影响因子: 5.4
作者:
Tao, Xinrong;Garron, Tania;Tseng, Chien-Te K.
通讯作者: Tseng, Chien-Te K.
DOI: 10.1038/nm.4131
发表时间: 2016-07-07
期刊: Nature medicine
影响因子: 82.9
作者:
Modjarrad K;Moorthy VS;Ben Embarek P;Van Kerkhove M;Kim J;Kieny MP
通讯作者: Kieny MP